Safety First,
Quality Always
SK pharmteco is the single customer-facing team comprised of
SK biotek Ireland, AMPAC Fine Chemicals, SK biotek Korea, AMPAC Analytical and Yposkesi.
Who We Are
Built on 80 years of experience, SK pharmteco is a trusted partner specializing in the manufacture of APIs and intermediates, viral vectors for gene and cell therapies, registered starting materials and analytical services for the pharmaceutical industry worldwide. Our global operations have the capability and capacity to support your needs from development through commercial production.
Our complementary assets and expertise enable us to provide the highest quality services to our customers.
Our Services
SK pharmteco specializes in the commercial and clinical production of APIs, Advanced Intermediates, Registered Starting Materials, Key Building Blocks and Viral Vectors. Our offerings include process R&D, analytical method development and stability, scale-up and optimization, validation and commercial production. Additionally, we offer extensive Adeno-Associated Viral (AAV) and Lentiviral vector development and cGMP production capabilities.
Our global operations include 6 cGMP manufacturing and development facilities across the United States, Korea, Ireland and France. We also operate a dedicated analytical services facility.
SK pharmteco is a leader in operational excellence and continuous improvement. Our highly skilled team delivers innovative solutions utilizing advanced technologies:
- Energetic Chemistry
- Continuous Flow Processing
- Chromatography: Simulated Moving Bed (SMB) & Batch
- High Potency (Up to 4 m3 scale & Down to 10 ng/m3 containment)
- Controlled Substances (Schedule II-V Manufacturing)
- Particle Engineering
- cGMP Manufacturing in Adherent & Suspension Systems for Viral Vectors
- Analytical & Process Development for Viral Vectors
We provide PAI and full regulatory support as well as complete confidentiality. We have a strong record of environmental, health, and safety performance. All our plants have been successfully audited by global regulatory agencies including the FDA (US), EMA (Europe), PMDA (Japan), and MFDS (Korea).
With a strong technology toolbox and ~1,000 m³ (~265,000 gal) of global small-molecule capacity plus a 5,000 m² facility dedicated to large molecules, we have the capability and capacity to support your needs across the full lifecycle.
The most trusted global partner in the delivery of innovative medicine
We are committed to changing the world through our unwavering dedication to life-saving therapies.
We enable our partners with cutting-edge technology, expertise and customer centricity, allowing them to bring breakthrough treatments to patients and delivering happiness and health to stakeholders everywhere.
Global Presence

6 Manufacturing Sites
~1,000 m³ (~265,000 gal)
Small Molecule Production Capacity
3 US (589 m³), 2 Korea (276 m³), 1 Ireland (97 m³)
5,000 m² Facility for
Large Molecule Manufacturing
1 France (expanding to 10,000 m²)

4 R&D Centers
US, Ireland, France, Korea

1 Analytical
Services Facility
US
80 Years of Experience
1,600+ Highly Skilled and Talented Workforce
approved by global regulatory agencies
FDA, EMA, ANSM, PMDA, MFDS
Advanced
Technologies
Diazomethane, Azide, Hydrazine, Ozone
Fixed bed, CSTR, PAT
Simulated Moving Bed (SMB), Batch
Up to 4 m3 (~1,000 gal) scale
Down to 10 ng/m3 containment
Schedule II-V Manufacturing
Schedule I By Request
Crystallization, MicronizationÂ
News

SK pharmteco Names Andrew Fenny Chief Commercial Officer
September 27, 2023 FOR IMMEDIATE RELEASE RANCHO CORDOVA, Ca. (September 27, 2023) – SK pharmteco, a global contract development and manufacturing

SK pharmteco is a Pharma Award Finalist for CPHI Barcelona 2023
On Sept. 15, 2023, CPHI Barcelona announced the finalists for the 2023 CPHI Pharma Awards. The awards ceremony will be

SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in Center for Breakthrough Medicines
September 19, 2023 FOR IMMEDIATE RELEASE – CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and